^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | ivospemin (SBP-101) (PARP inhibitor, Ornithine decarboxylase inhibitor, CASP3 stimulant, AMD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101
Published date:
06/30/2020
Excerpt:
Sun BioPharma, Inc...announced receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product, SBP-101, being developed for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in combination with gemcitabine and nab-paclitaxel.
Secondary therapy:
gemcitabine + albumin-bound paclitaxel
